|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Aimovig
|
|
gptkbp:capacity
|
0.5 m L
|
|
gptkbp:clinical_trial
|
gptkb:EVOLVE-1
gptkb:EVOLVE-2
Phase 3
ARISE
|
|
gptkbp:contraindication
|
hypersensitivity to erenumab
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:drug_interactions
|
none known
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
pre-filled syringe
autoinjector
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aimovig
|
|
gptkbp:indication
|
chronic migraine
episodic migraine
|
|
gptkbp:ingredients
|
gptkb:erenumab
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
CGRP receptor antagonist
|
|
gptkbp:patient_education
|
important
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
long half-life
CGRP inhibition
|
|
gptkbp:previous_name
|
gptkb:erenumab
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
recommended
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research_focus
|
migraine treatment
CGRP pathway
|
|
gptkbp:service_frequency
|
once monthly
|
|
gptkbp:side_effect
|
gptkb:depression
anxiety
fatigue
nausea
insomnia
constipation
dry mouth
injection site reactions
muscle spasms
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
migraine prevention
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|